Oxford BioDynamics Ltd (OBD) is a health-care service company with a proprietary biomarker discovery platform, EpiSwitch™, based on the latest advances in the mechanisms of gene expression, non-coding RNA and epigenetics.

The EpiSwitch™ biomarker discovery platform offers a highly effective means of new product development for applications in screening, early detection, monitoring and prognosis of disease and chronic conditions associated with aberrant gene expression such as oncology, inflammatory, auto-immune, metabolic, cardiovascular and neurodegenerative conditions.